-
Diagnostics World | You might be forgiven for calling the tone of a panel on diagnostics held at last week’s Precision Medicine Tri-Con “optimistic”. But you would be corrected: it isn’t optimism, it’s math.
Apr 2, 2024
-
Diagnostics World | Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations; X-Therma plan to scale global commercial operations and facilitate progression into the clinical stage with FDA Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations; and more.
Mar 27, 2024
-
Diagnostics World | Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations; X-Therma plan to scale global commercial operations and facilitate progression into the clinical stage with FDA Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations; and more.
Mar 26, 2024
-
Diagnostics World | The single biggest risk factor for autoimmune disease is being biologically a female and many explanations have been proposed as to why that is, among them sex hormones and the X chromosome with its large number of immune-related genes.
Mar 21, 2024
-
Diagnostics World | When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less.
Mar 20, 2024
-
Diagnostics World | Scientists in the Georgia Tech Integrated Cancer Research Center (ICRC) are proposing a new, more realistic approach to diagnosing cancer that provides a probabilistic statement about the likelihood of developing it, much like how cholesterol tests are used to assess heart disease risk. Probabilities are based on an individual’s metabolic profile and the first population group to be targeted are women at high risk for ovarian cancer.
Mar 19, 2024
-
Diagnostics World | Scientists from a trio of countries are calling for a new, more comprehensive way of classifying Parkinson’s disease for diagnostic research purposes that considers an individual’s biology. The disorder might thereby be detected before patients have any symptoms, as is now the case for cancer and diabetes.
Mar 14, 2024
-
Diagnostics World | For roughly half of patients with recurrence of often-deadly glioblastoma multiforme (GBM), their tumors are characterized by cells that look a lot like healthy neurons. The mimicry trick was discovered by proteomics, which has opened a view to tumor alterations unavailable through genetics alone.
Mar 12, 2024
-
Diagnostics World | Biomedical engineers have a significant role to play in the development and optimization of liquid biopsies to further precision oncology. Although molecular profiling of tumors has entered mainstream clinical practice, the wait time for identifying the best treatment for individual patients could be shortened by blood-testing devices designed to efficiently capture circulating tumor cells (CTCs) and cancer-specific protein markers on their surface.
Mar 7, 2024
-
Diagnostics World | A team of researchers from Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard are developing priming agents to temporarily boost levels of cell-free DNA (cfDNA) for cancer diagnostics. It’s an entirely new concept that could do for liquid biopsies what contrast agents have done for ultrasound and MRI.
Mar 6, 2024
-
Diagnostics World | A machine learning method dubbed A-PLUS (Alu Profile Learning Using Sequencing) recently demonstrated its ability to pick up cancers earlier and with smaller blood draws than is required for whole genome sequencing. This makes possible a future where people might get annual blood draws to check for cancer based on the “fragmentation pattern” of cell-free DNA (cfDNA) circulating in their blood.
Mar 5, 2024
-
Diagnostics World | Owkin-Amazon Web Services partner on AI-assisted diagnostics, Diagnexia announced a significant collaborative agreement with Aga Khan University Hospital (AKUH), Nairobi; X-trodes announced that the U.S. Food and Drug Administration has granted 510(k) clearance for X-trodes' Smart Skin solution (marketed as X-trodes System M); PathAI has announced an expanded and exclusive relationship with Roche Tissue Diagnostics (RTD) that will bring AI-enabled interpretation to companion diagnostics; and more.
Feb 29, 2024
-
Diagnostics World | Freenome will advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform; Capitainer will continue its journey toward becoming the foremost provider of self-sampling solutions with new funding; Circular Genomics plans to build and scale commercial operations in preparation for the launch of the world's first circular RNA-based clinical assay; and more.
Feb 28, 2024
-
Diagnostics World | Among the sequencing news at AGBT earlier this month, Ultima Genomics announced the commercial launch of its UG 100 ultra-high throughput sequencing platform.
Feb 27, 2024
-
Diagnostics World | It is time for clinical laboratories to push for cytomegalovirus (CMV) testing as part of the standard newborn screening process. We have seen some progress on this front recently, with Minnesota becoming the first state in the US to approve universal CMV screening at birth. However, Minnesota should not stand alone; newborns everywhere would benefit from CMV screening.
Feb 23, 2024
-
Diagnostics World | A revolution is underway in the diagnostics world that is reminiscent of what transpired in the computing field before the advent of PCs and smartphones. The unimagined possibilities of today will come from democratizing technology so that instead of sending patients to the lab, the lab will get sent to patients—and, ultimately, be available to them in the form of at-home testing kits.
Feb 21, 2024
-
Diagnostics World | Researchers in Spain are advocating the use of sweat in metabolomics studies to measure the severity of sleep apnea. It’s an ideal alternative to blood and urine because the sampling is noninvasive and accessible, and the biofluid doesn’t require much manipulation by the test operator that can introduce variability.
Feb 20, 2024
-
Diagnostics World | In the future, it may be possible for people to get a read on viruses circulating in their neighborhood in the same way they now do to assess current weather conditions before hitting the road. The means would be some sort of digitized community health report, an early version of which is already being produced for 10 cities across Texas.
Feb 15, 2024
-
Diagnostics World | Researchers in California have shown that breast cancer patients with RNA expression levels of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) in the bottom 50th percentile can confidently be treated with Keytruda (pembrolizumab) as well as surgery. Their cancer would have a zero percent chance of metastasizing in seven years.
Feb 13, 2024
-
Diagnostics World | If artificial intelligence (AI) is to be as insightful as possible in advancing human health, it is not enough to have a patchwork of out-of-context data from which to draw conclusions. That is unfortunately the current situation and at the cost of lost opportunities to better treat patients, identify early biomarkers of disease, and recognize the right endpoints in clinical trials—not to mention eradicating existing biases against marginalized groups of people.
Feb 8, 2024